Theriva Biologics, Inc.

Contributing Author

Recent Articles by Theriva Biologics, Inc.

Aug-11	Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results TOVX GlobeNewswire
Aug-06	Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma TOVX GlobeNewswire
Jul-07	Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma TOVX -7.07% GlobeNewswire
Jun-11	Theriva Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research TOVX +26.08% GlobeNewswire
May-05	Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results TOVX GlobeNewswire
Apr-17	Theriva Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting TOVX TOVX +59.41% GlobeNewswire
Mar-23	Theriva Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma TOVX +8.42% GlobeNewswire
Mar-12	Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
Feb-18	Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications TOVX +6.25% GlobeNewswire
Feb-03	Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 TOVX GlobeNewswire
Dec-29	Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) TOVX GlobeNewswire
Nov-12	Theriva Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results TOVX +8.05% GlobeNewswire
Oct-24	Theriva Biologics Provides Response to Unusual Market Action TOVX TOVX -5.04% GlobeNewswire
Oct-16	Theriva Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds TOVX -48.68% GlobeNewswire
Oct-13	Theriva Biologics Announces Upcoming Presentations at Medical Meetings TOVX GlobeNewswire
Oct-06	Theriva Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) TOVX GlobeNewswire
Aug-11	Theriva Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results TOVX +14.02% GlobeNewswire
May-27	Theriva Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer TOVX -5.49% GlobeNewswire
May-14	Theriva Biologics Reports First Quarter 2025 Operational Highlights and Financial Results TOVX GlobeNewswire
May-08	Theriva Biologics Announces Closing of $7.5 Million Public Offering TOVX -20.59% TOVX -17.62% GlobeNewswire
May-07	Theriva Biologics Announces Pricing of $7.5 Million Public Offering TOVX -40.44% GlobeNewswire
May-07	Theriva Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients TOVX -40.44% GlobeNewswire

Theriva Biologics, Inc.

Recent Articles by Theriva Biologics, Inc.

Upgrade your Finviz experience